|
|
Dermatologists' Case
Files:
Use of
Immune Response Modifier Therapy in Challenging
Patients
A supplement to Skin & Allergy
News, supported by an educational grant from 3M
Pharmaceuticals and designated by the American Academy of
Dermatology (AAD) for AAD continuing medical educational
(CME) credit.
Topics
- Introduction
- Sebaceous Carcinoma in an Elderly
Patient
- Extensive Actinic Keratoses
- Actinic Keratoses and Warts in a
Kidney Transplant
Recipient
|
Faculty
Hilary E.
Baldwin, MD
Associate
Professor of Clinical Dermatology
Department of Dermatology
SUNY Downstate Medical Center
Brooklyn, N.Y.
May J. Chow, MD
Director of Dermatology
Wellgroup Health Partners
Chicago Heights, Ill.
Clinical Assistant Professor of
Medicine and Dermatology
Midwestern
University
Downers Grove,
Ill |
Back to top  |
Faculty
Disclosures
The faculty of this CME activity
disclose the following:
| Faculty Member |
|
|
| Hilary E. Baldwin, MD |
Dr. Baldwin has nothing to disclose
nor does she discuss the unlabeled use of any drugs. |
|
| May J.
Chow, MD |
Dr. Chow has received honoraria
from 3M Pharmaceuticals. She discusses the alternatives
to approved dosage regimens of imiquimod; the unlabeled
use of tazarotene as an adjunct to imiquimod therapy in
actinic keratosis; prophylactic maintenance treatment
with imiquimod; and the use of imiquimod to treat
sebaceous carcinoma or nodular basal cell
carcinoma. |
| |
| Back to top |
Target Audience
This activity has been developed for
dermatologists and other healthcare professionals involved
in the diagnosis and treatment of skin
conditions for which immune response modifier therapy may
be considered. |
Educational
Needs
The treatment of many commonly
encountered skin disorders necessitates elimination of
lesions. Such cutaneous disorders include actinic keratoses,
external anogenital warts, superficial basal cell
carcinomas, squamous cell carcinomas, and common warts.
Historically, these lesions have been treated with a variety
of surgical and/or chemical lesion-destructive modalities.
These therapies have varied in their success rates; in
addition, they often produce adverse effects such as pain,
swelling, and scarring.
Within the past decade, the concept of
local immune response modifier (IRM) treatment for many of
these diseases has emerged. With IRM therapy, topical
application of the medication produces a local upregulation
of activity in both the innate and the acquired immune
system, yielding proven, safe, antiviral and antitumor
activity with limited side effects and ease of application.
The results of well-controlled clinical
trials form the foundation of any evidence-based approach to
medical treatment. In treating individual patients, however,
clinicians also receive valuable knowledge from their own
experience and that of their colleagues. Using case studies
as a basis, this supplement offers the clinical experiences
of experts who have used imiquimod in a variety of skin
diseases. |
| Back to top |
Learning Objectives
By reading and studying this
supplement, participants should be able to:
·
Discuss the indications and dosing
schedule for the use of imiquimod that are currently
approved by the US Food and Drug Administration.
·
Describe the experience of clinicians
who treated an elderly patient with sebaceous carcinoma in a
case presented in this supplement.
·
Discuss the
treatment regimen used for treating a patient with extensive
actinic keratoses on the face and upper extremities.
|
| Back to top |
CME
Recognition
This Skin & Allergy News
supplement is recognized by the American Academy
of Dermatology (AAD) for 1 hour of AAD Category 1 CME credit
and may be used toward the American Academy of Dermatology’s
Continuing Medical Education Award. This program was
developed in accordance with the Accreditation Council for
Continuing Medical Education guidelines.
Term of
Approval: March 2006—February 28, 2007
Copyright
© 2006 Elsevier Inc.
|